SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function.

[1]  L. Guarente,et al.  SIRT1 is a positive regulator of in vivo bone mass and a therapeutic target for osteoporosis , 2017, PloS one.

[2]  O. Abdel-Wahab,et al.  Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression , 2017, Cell.

[3]  R. Deberardinis,et al.  Ascorbate regulates haematopoietic stem cell function and leukaemogenesis , 2017, Nature.

[4]  A. Verma,et al.  Stem and progenitor cell alterations in myelodysplastic syndromes. , 2017, Blood.

[5]  S. Baylin,et al.  Acetylation Enhances TET2 Function in Protecting against Abnormal DNA Methylation during Oxidative Stress. , 2017, Molecular cell.

[6]  S. Miyano,et al.  Dynamics of clonal evolution in myelodysplastic syndromes , 2016, Nature Genetics.

[7]  B. Ebert,et al.  The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia , 2016, Nature Reviews Cancer.

[8]  Cristina Leoni,et al.  TET2 Regulates Mast Cell Differentiation and Proliferation through Catalytic and Non-catalytic Activities. , 2016, Cell reports.

[9]  W. Han,et al.  Acetylome study in mouse adipocytes identifies targets of SIRT1 deacetylation in chromatin organization and RNA processing. , 2016, Archives of biochemistry and biophysics.

[10]  B. Doble,et al.  GSK3 Deficiencies in Hematopoietic Stem Cells Initiate Pre-neoplastic State that Is Predictive of Clinical Outcomes of Human Acute Leukemia. , 2016, Cancer cell.

[11]  L. Guarente,et al.  The multifaceted functions of sirtuins in cancer , 2015, Nature Reviews Cancer.

[12]  J. Issa,et al.  TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia. , 2015, Cancer research.

[13]  B. Porse,et al.  Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis , 2015, Genes & development.

[14]  Xian Chen,et al.  CRL4(VprBP) E3 ligase promotes monoubiquitylation and chromatin binding of TET dioxygenases. , 2015, Molecular cell.

[15]  Ø. Bruserud,et al.  SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. , 2014, Cell stem cell.

[16]  L. Bullinger,et al.  SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. , 2014, Blood.

[17]  P. Elliott,et al.  A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes. , 2014, British journal of clinical pharmacology.

[18]  G. Garcia-Manero,et al.  An MDS xenograft model utilizing a patient-derived cell line , 2014, Leukemia.

[19]  R. Willemze,et al.  Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial , 2014, Annals of Hematology.

[20]  S. Miyano,et al.  Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations , 2014, Haematologica.

[21]  Ze Li,et al.  Crystal Structure of TET2-DNA Complex: Insight into TET-Mediated 5mC Oxidation , 2013, Cell.

[22]  Carrie A. Williams,et al.  Sirt1 ablation promotes stress-induced loss of epigenetic and genomic hematopoietic stem and progenitor cell maintenance , 2013, The Journal of experimental medicine.

[23]  L. Aravind,et al.  Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX , 2013, Nature.

[24]  Y. Xiong,et al.  R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. , 2013, Cancer cell.

[25]  Dudley Lamming,et al.  Evidence for a Common Mechanism of SIRT1 Regulation by Allosteric Activators , 2013, Science.

[26]  Guangsen Zhang,et al.  Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes , 2013, Leukemia & lymphoma.

[27]  Kuniaki Saito,et al.  Activation-Induced Cytidine Deaminase Alters the Subcellular Localization of Tet Family Proteins , 2012, PloS one.

[28]  S. Desiderio,et al.  Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model. , 2012, Blood.

[29]  T. Holyoake,et al.  Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. , 2012, Cancer cell.

[30]  A. Rao,et al.  TET2: epigenetic safeguard for HSC. , 2011, Blood.

[31]  Wenyong Zhang,et al.  Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. , 2011, Blood.

[32]  O. Abdel-Wahab,et al.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. , 2011, Cancer cell.

[33]  H. Votavova,et al.  Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome , 2011, European Journal of Human Genetics.

[34]  T. Haferlach,et al.  Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML , 2010, Leukemia.

[35]  B. Ebert.  Preface. The biology and treatment of myelodysplastic syndrome. , 2010, Hematology/Oncology Clinics of North America.

[36]  M Cazzola,et al.  Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells , 2010, Leukemia.

[37]  Y. Tohyama,et al.  Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis , 2010, Leukemia.

[38]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[39]  W. Gu,et al.  How does SIRT1 affect metabolism, senescence and cancer? , 2009, Nature Reviews Cancer.

[40]  T. Fry,et al.  Transplantation of a myelodysplastic syndrome by a long-term repopulating hematopoietic cell , 2008, Proceedings of the National Academy of Sciences.

[41]  Ying Guo,et al.  SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization. , 2008, Cell stem cell.

[42]  Amy V. Lynch,et al.  Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes , 2007, Nature.

[43]  P. Distefano,et al.  Inhibition of SIRT1 Catalytic Activity Increases p53 Acetylation but Does Not Alter Cell Survival following DNA Damage , 2006, Molecular and Cellular Biology.

[44]  F. Alt,et al.  Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[46]  T. Ueda,et al.  Establishment and characterization of a novel myeloid cell line from the bone marrow of a patient with the myelodysplastic syndrome , 1994, British journal of haematology.

[47]  F. Hamdy,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[48]  D. Starczynowski,et al.  Deregulation of microRNAs in myelodysplastic syndrome , 2012, Leukemia.